Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Ruzurgi (amifampridine) for the treatment of LEMS

Drug Name

Ruzurgi (amifampridine)

Developers

Jacobus Pharmaceutical

Therapy Class

Potassium channel blocker

Product Description

3,4-diaminopyridine (3,4-DAP)

Current Indication

Lambert-Eaton myasthenic syndrome

Market Sector

Market Sector

Development Status

Approved in the US
Expand
Close
Close
Close

Go Top